Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

A-H Premium Weekly: China Southern, Shanghai Junshi, Shanghai Haohai, Shanghai Fudan

A-H Premium Weekly: Asymchem Lab, China Comm Construction

A-H Premium Weekly: CICC, Great Wall Motor, Cansino

A-H Premium Weekly: Healthcare Led Premium Decline

A-H Premium Weekly: Real Estate at 52 Week High

A-H Premium Weekly: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Health care / Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 138 stocks over the last week.</li>
<li>Real Estate, Industrials, Utilities Led the week on week A-H premium decline of 2.7ppt. </li>
<li>We highlight stocks including Shanghai Junshi, CIMC Vehicles, and CRCC Corp.</li>
</ul>


We analyse the changes of A/H premium on 138 stocks over the last week.
Real Estate, Industrials, Utilities Led the week on week A-H premium decline of 2.7ppt. 
We highlight stocks including Shanghai Junshi, CIMC Vehicles, and CRCC Corp.


A-H Premium Weekly: Real Estate, Industrials, Utilities Led the Decline